Eplontersen (Wainua): The Antisense TTR Silencer That Missed in the Heart - What CARDIO-TTRansform Means Next to Vutrisiran's Success (August 23, 2026)
Table of Contents
- Two ways to silence one protein
- What eplontersen is
- Antisense vs siRNA: same goal, different machinery
- From inotersen to eplontersen
- NEURO-TTRansform: winning in the nerves
- CARDIO-TTRansform: stumbling in the heart
- The monotherapy signal - and the tafamidis problem
- Why the contrast with vutrisiran matters
- Where eplontersen fits in the Ionis platform
- The bottom line and the cautions
Two ways to silence one protein
For decades, transthyretin amyloidosis had no treatment that touched its cause. Today it has two families of drugs that attack the root problem - the transthyretin (TTR) protein your liver makes and that, when it misfolds, deposits as amyloid in nerves and heart. One family are the 'silencers,' which stop the liver from making so much TTR. Within that family are two rival chemistries: small interfering RNAs (siRNAs) like patisiran, vutrisiran and inclisiran, and antisense oligonucleotides (ASOs) like eplontersen. Eplontersen - sold as Wainua in the US and Wainzua in Europe by Ionis and AstraZeneca - is the antisense answer to the siRNA drug vutrisiran. In 2026 the two drugs' cardiomyopathy trials delivered opposite verdicts, and that contrast is now one of the most important stories in the field.
What eplontersen is
Eplontersen is a once-monthly, self-administered injection given under the skin with an autoinjector (or as a pre-filled syringe by a clinician). Chemically it is a short, modified single strand of nucleic acid - an antisense oligonucleotide - bolted to a triantennary GalNAc sugar tag. The GalNAc tag is recognized almost exclusively by a receptor on liver cells, so the drug funnels straight to the hepatocytes where TTR is produced. Once inside, it base-pairs with the messenger RNA for TTR and recruits an enzyme called RNase H1 to chop that mRNA up, so the protein is never made. In trials this knocks circulating TTR down by around 80 percent, drying up the raw material for amyloid.
Antisense vs siRNA: same goal, different machinery
It is easy to lump silencers together, but eplontersen and vutrisiran work through different cellular machinery. An siRNA like vutrisiran plugs into the RNA interference pathway and its RISC complex to destroy the target mRNA. An antisense drug like eplontersen instead recruits the enzyme RNase H1 to cleave the mRNA where the drug binds. Both end up lowering TTR by a similar amount, but the delivery, dosing and chemistry differ - eplontersen is a monthly ASO, vutrisiran a quarterly siRNA - and, as 2026 showed, they may not behave identically in every tissue.
From inotersen to eplontersen
Eplontersen did not appear from nowhere. Its predecessor, inotersen (Tegsedi), was Ionis's first-generation TTR antisense drug - effective, but injected weekly and burdened by risks of low platelets and kidney problems that required regular monitoring. Bolting on the GalNAc sugar tag changed everything: it let a much smaller dose reach the liver, cutting the injection schedule to once a month and markedly improving tolerability. Eplontersen is that second-generation, GalNAc-conjugated successor - the same idea inotersen pioneered, made low-dose, monthly and cleaner.
NEURO-TTRansform: winning in the nerves
Eplontersen's approval came from NEURO-TTRansform, a Phase 3 trial in adults with the polyneuropathy of hereditary ATTR. Patients received eplontersen 45 mg every four weeks, and the study compared them against the placebo group from the earlier inotersen trial. Eplontersen significantly improved a standardized measure of nerve impairment (mNIS+7) and quality of life, and reduced serum TTR by about 81 percent. On that basis the FDA approved Wainua in December 2023 for hereditary ATTR polyneuropathy; it is now approved in more than 20 countries, including the EU as Wainzua.
CARDIO-TTRansform: stumbling in the heart
The bigger prize was ATTR cardiomyopathy (ATTR-CM), the far more common and often fatal form of the disease. CARDIO-TTRansform was the largest ATTR-CM trial ever enrolled: 1,432 patients across 130 sites in 20 countries, randomized to eplontersen 45 mg or placebo every four weeks on top of standard care, with a primary composite of cardiovascular death plus recurrent cardiovascular events through Week 140. On July 9, 2026, Ionis and AstraZeneca announced the trial had missed that primary endpoint. In this contemporary population, adding eplontersen did not produce a statistically significant benefit.
The monotherapy signal - and the tafamidis problem
The result was not a flat negative. The trial ran in the tafamidis era: 57 percent of patients were already on a TTR stabilizer at baseline, and another 24 percent started one during the study. In the prespecified subgroup of patients on eplontersen alone - no background stabilizer - fewer cardiovascular events occurred, a nominally significant benefit (reported hazard ratio around 0.71). But patients already stabilized on tafamidis or acoramidis saw no added effect. The reading many took away: once a patient's TTR is stabilized, layering a silencer on top may add little - a question the whole field is now wrestling with.
Why the contrast with vutrisiran matters
Here is what makes 2026 so instructive. Vutrisiran's HELIOS-B trial tested a TTR silencer in ATTR-CM mostly on top of tafamidis - and it succeeded, cutting the composite of death and cardiovascular events (hazard ratio 0.72) and becoming the first RNAi drug proven to reduce cardiovascular outcomes. Eplontersen's CARDIO-TTRansform tested the same silencing strategy, also largely on a stabilizer background - and missed. Whether the difference reflects the chemistries (siRNA vs antisense), the trial populations and eras, the endpoints, or chance is now the central debate, and the full CARDIO-TTRansform data were brought to the ESC Congress in August 2026 for scrutiny.
Where eplontersen fits in the Ionis platform
Beyond TTR, eplontersen is a flagship of Ionis's GalNAc-conjugated antisense platform, which it shares with olezarsen (an APOC3 antisense drug for high triglycerides) and pelacarsen (a lipoprotein(a) antisense drug in cardiovascular outcomes testing). Together they are the antisense counterparts to the GalNAc-siRNA silencers - inclisiran, olpasiran, lepodisiran, zerlasiran, zilebesiran, zodasiran, solbinsiran and plozasiran - that PepTracker Pro tracks across the cardiometabolic space. Eplontersen is the clearest head-to-head test of antisense against siRNA in the same disease.
The bottom line and the cautions
Eplontersen is a genuine advance for hereditary ATTR polyneuropathy: a once-a-month, self-injected silencer that lowers TTR by roughly 80 percent and improves nerve outcomes, with a far cleaner profile than the drug it succeeded. But its 2026 cardiomyopathy readout is a reminder that lowering a protein does not guarantee better heart outcomes, especially on top of a stabilizer. It is an approved prescription medicine - not a supplement, and anything sold online as 'eplontersen' or 'Wainua' outside a pharmacy is unverified and unsafe. Because TTR carries vitamin A, patients supplement it; the drug treats ATTR, not AL, amyloidosis, so the amyloid type must be confirmed first. This article is educational and not medical advice; decisions about ATTR treatment - whether to silence, stabilize, or both - belong with a specialist.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) - AstraZeneca (July 9, 2026) Source
- [2] Update on CARDIO-TTRansform Phase 3 trial of eplontersen - Ionis Pharmaceuticals (July 8, 2026) Source
- [3] Coelho T, et al. - Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy (NEURO-TTRansform), JAMA (2023) Source
- [4] Wainua (eplontersen) granted first-ever regulatory approval in the US - AstraZeneca (December 2023) Source
- [5] CARDIO-TTRansform - ClinicalTrials.gov, NCT04136171 Source
- [6] Fontana M, et al. - Vutrisiran in Patients with ATTR Cardiomyopathy (HELIOS-B), NEJM (2024) Source
Related Articles
Inclisiran (Leqvio): The Twice-a-Year siRNA Injection That Halves LDL Cholesterol - How PCSK9 Silencing Works and Where the Outcomes Data Stand (August 17, 2026)
Statins and daily pills lose their power when patients stop taking them. Inclisiran (Leqvio) takes a different route: a subcutaneous injection given just twice a year that silences the liver protein PCSK9 and cuts LDL cholesterol by about half. It was the first RNA-interference medicine approved for a common chronic cardiovascular condition, and in 2025 the FDA broadened its label to first-line use. Here is how PCSK9 silencing works, what the ORION trials showed, how inclisiran compares with the PCSK9 antibodies, and why the VICTORION outcomes trials are the test that still matters.
Most gene-silencing drugs move a lab value. Vutrisiran moved mortality. Alnylam's quarterly subcutaneous injection silences the TTR gene in the liver to treat ATTR amyloidosis, and in the HELIOS-B trial it became the first RNAi therapeutic proven to reduce cardiovascular death and events in ATTR cardiomyopathy. Here is how it works, from GalNAc chemistry to the heart data that earned its 2025 label.